[CAS NO. 945721-28-8] Daratumumab
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [945721-28-8]
Catalog
HY-P9915
Brand
MCE
CAS
945721-28-8
DESCRIPTION [945721-28-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | - |
| SMILES | [Daratumumab] |
For research use only. We do not sell to patients.
Summary
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition [1] [2] .
In Vitro
Daratumumab (Anti-Human CD38) induces potent Ab-dependent cellular cytotoxicity in CD38-expressing lymphoma- and MM-derived cell lines [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Daratumumab (i.p.; 0.5 mg/kg; 14 d after challenge with Daudi-luc cells) inhibits outgrowth of CD38-expressing tumor cells in mouse xenograft tumor models [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 8- to 10-wk-old C.B-17 SCID mice (luciferase-expressing Daudi cells) [2] |
| Dosage: | 0.5 mg/kg |
| Administration: | I.p.; 14 day after challenge with Daudi-luc cells |
| Result: | Effectively inhibited tumor growth compared with control-treated animals in which tumor grew rapidly and therefore required euthanasia on day 35. On day 28 and day 35, tumor size in Daratumumab-treated animals was significantly different from the control. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03589222 | PETHEMA Foundation |
Refractory Multiple Myeloma
|
July 15, 2018 | Phase 2 |
| NCT03314181 | AbbVie|Janssen Research & Development, LLC |
Multiple Myeloma
|
April 2, 2018 | Phase 2 |
| NCT04756401 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
October 31, 2022 | Phase 2 |
| NCT03289299 | International Myeloma Foundation|Amgen|Janssen Scientific Affairs, LLC|Celgene|Trevie, Inc. |
Smoldering Multiple Myeloma
|
May 25, 2018 | Phase 2 |
| NCT01665794 | University of Chicago|National Cancer Institute (NCI)|Multiple Myeloma Research Foundation |
Multiple Myeloma
|
August 13, 2012 | Phase 1|Phase 2 |
| NCT05455320 | Janssen Research & Development, LLC |
Relapsed or Refractory Multiple Myeloma
|
October 13, 2022 | Phase 3 |
| NCT05434689 | University of Alabama at Birmingham |
Multiple Myeloma
|
December 2022 | Phase 1|Phase 2 |
| NCT03669445 | University Hospital, Toulouse |
Multiple Myeloma
|
December 31, 2018 | Phase 2 |
| NCT03989414 | Celgene |
Multiple Myeloma
|
September 30, 2019 | Phase 1|Phase 2 |
| NCT02060188 | Bristol-Myers Squibb |
Microsatellite Unstable Colorectal Cancer|Microsatellite Stable Colorectal Cancer|Mismatch Repair Proficient Colorectal Cancer|Mismatch Repair Deficient Colorectal Cancer
|
March 12, 2014 | Phase 2 |
| NCT03475628 | Hellenic Society of Hematology|Janssen Pharmaceuticals |
Multiple Myeloma
|
February 21, 2018 | Phase 2 |
| NCT04124497 | Fondazione EMN Italy Onlus |
Multiple Myeloma|Deletion 17P Syndrome
|
July 1, 2019 | Phase 2 |
| NCT03701321 | National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
January 25, 2019 | Phase 1|Phase 2 |
| NCT05259839 | TeneoOne Inc. |
Relapsed+Refractory Multiple Myeloma
|
October 20, 2022 | Phase 1 |
| NCT05280275 | Hellenic Society of Hematology|GlaxoSmithKline |
Multiple Myeloma|Neoplasms|Neoplasms, Plasma Cell|Gammopathy, Monoclonal|Paraproteinemias|Blood Protein Disorders|Haematologic Disease|Corneal Disease
|
March 15, 2022 | Phase 1|Phase 2 |
| NCT03217812 | Janssen Research & Development, LLC |
Multiple Myeloma
|
November 23, 2017 | Phase 3 |
| NCT04009109 | Alliance Foundation Trials, LLC.|Janssen Scientific Affairs, LLC|Celgene Corporation|Takeda |
Myeloma, Multiple
|
October 21, 2020 | Phase 2 |
| NCT04264884 | Janssen Research & Development, LLC |
|
||
| NCT02419118 | Vejle Hospital |
Multiple Myeloma
|
January 2015 | Phase 2|Phase 3 |
| NCT04975997 | Celgene |
Multiple Myeloma
|
June 23, 2022 | Phase 3 |
| NCT02413489 | Janssen Research & Development, LLC |
Lymphoma, Mantle-Cell|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular
|
September 2, 2015 | Phase 2 |
| NCT03201965 | Janssen Research & Development, LLC |
Amyloidosis
|
October 5, 2017 | Phase 3 |
| NCT05284591 | iOMEDICO AG |
Multiple Myeloma|Newly Diagnosed|Transplant Ineligible|Patient Satisfaction|Patient Preference|Personal Satisfaction
|
July 6, 2022 | |
| NCT03901963 | Janssen Research & Development, LLC |
Multiple Myeloma
|
April 26, 2019 | Phase 3 |
| NCT04722146 | Janssen Research & Development, LLC |
Multiple Myeloma
|
March 12, 2021 | Phase 1 |
| NCT05403138 | Tianjin Medical University General Hospital |
Neuromyelitis Optica|Neuromyelitis Optica Spectrum Disorder|NMO Spectrum Disorder
|
November 1, 2022 | Phase 2|Phase 3 |
| NCT05363111 | City of Hope Medical Center|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
November 30, 2022 | Phase 1 |
| NCT03837509 | Incyte Corporation |
Relapsed or Refractory Multiple Myeloma
|
September 25, 2019 | Phase 1|Phase 2 |
| NCT03187262 | Dana-Farber Cancer Institute|Janssen, LP |
Waldenström Macroglobulinemia
|
November 27, 2017 | Phase 2 |
| NCT04113018 | Wake Forest University Health Sciences|Amgen|Celgene|Janssen, LP |
Multiple Myeloma
|
November 12, 2019 | Phase 2 |
| NCT03320707 | Janssen Research & Development, LLC |
Healthy
|
October 16, 2017 | Phase 1 |
| NCT04205240 | Srinivas Devarakonda|Ohio State University Comprehensive Cancer Center |
Recurrent Plasma Cell Myeloma
|
May 27, 2020 | Phase 2 |
| NCT04121260 | Janssen Research & Development, LLC |
Multiple Myeloma
|
December 25, 2019 | Phase 1 |
| NCT05451771 | Rajshekhar Chakraborty, MD|Genentech, Inc.|Columbia University |
AL Amyloidosis
|
October 26, 2022 | Phase 1|Phase 2 |
| NCT05289687 | Eastern Cooperative Oncology Group|Janssen, LP |
T-cell Acute Lymphoblastic Leukemia
|
June 16, 2022 | Phase 2 |
| NCT03207542 | M.D. Anderson Cancer Center|Janssen Scientific Affairs, LLC |
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
|
July 2018 | Phase 2 |
| NCT03697655 | Polish Myeloma Consortium|Janssen-Cilag Ltd.|Bioscience, S.A. |
Multiple Myeloma
|
December 10, 2018 | Phase 2 |
| NCT05497804 | Mayo Clinic|National Cancer Institute (NCI) |
ISS Stage III Plasma Cell Myeloma|Plasma Cell Myeloma
|
September 22, 2022 | Phase 2 |
| NCT05581875 | Hellenic Society of Hematology|GlaxoSmithKline |
Multiple Myeloma|Multiple Myeloma in Relapse|Neoplasms|Gammopathy, Monoclonal|Paraproteinemias|Blood Protein Disorders|Haematologic Disease|Corneal Disease|Neoplasms, Plasma Cell
|
October 20, 2022 | Phase 1|Phase 2 |
| NCT05088330 | The First Affiliated Hospital of Soochow University |
Newly Diagnosed Multiple Myeloma
|
December 1, 2021 | Not Applicable |
| NCT05408026 | Alliance Foundation Trials, LLC.|Janssen, LP|Celgene |
Relapsed or Refractory Multiple Myeloma
|
October 1, 2022 | Phase 1|Phase 2 |
| NCT03829371 | University of Turin, Italy |
Multiple Myeloma
|
January 3, 2019 | Phase 4 |
| NCT03412565 | Janssen Research & Development, LLC |
Multiple Myeloma
|
April 26, 2018 | Phase 2 |
| NCT03357952 | Janssen Research & Development, LLC |
Multiple Myeloma
|
November 16, 2017 | Phase 2|Phase 3 |
| NCT04827979 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|Bristol-Myers Squibb|PPD|Rho Federal Systems Division, Inc. |
Highly Sensitized Prospective Kidney Transplant Recipients
|
November 1, 2021 | Phase 1|Phase 2 |
| NCT04635189 | University of Rochester |
Multiple Myeloma
|
July 27, 2021 | Phase 2 |
| NCT04892446 | Gilead Sciences |
Multiple Myeloma
|
November 9, 2021 | Phase 2 |
| NCT02977494 | Universitätsklinikum Hamburg-Eppendorf |
Multiple Myeloma
|
June 2016 | Phase 2 |
| NCT04776018 | Takeda |
Relapsed and+or Refractory Multiple Myeloma (RRMM)
|
April 20, 2021 | Phase 1|Phase 2 |
| NCT02626481 | University Hospital, Lille|Janssen, LP|Intergroupe Francophone du Myelome |
Multiple Myeloma
|
December 28, 2015 | Phase 2 |
| NCT04270175 | Weill Medical College of Cornell University|Janssen Scientific Affairs, LLC |
Amyloid|AL Amyloidosis|Refractory AL Amyloidosis
|
April 14, 2021 | Phase 2 |
| NCT03537599 | Sumithira Vasu|Ohio State University Comprehensive Cancer Center |
Minimal Residual Disease|Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia
|
January 10, 2020 | Phase 1|Phase 2 |
| NCT03622775 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma
|
April 11, 2019 | Phase 2 |
| NCT02477891 | Janssen Research & Development, LLC |
Multiple Myeloma
|
||
| NCT03283917 | M.D. Anderson Cancer Center|Janssen Pharmaceuticals|Takeda |
Newly Diagnosed Primary Amyloidosis|Recurrent Primary Amyloidosis|Refractory Primary Amyloidosis
|
February 7, 2018 | Phase 1 |
| NCT02541383 | Intergroupe Francophone du Myelome|HOVON - Dutch Haemato-Oncology Association|Janssen Research & Development, LLC |
Multiple Myeloma
|
September 2015 | Phase 3 |
| NCT03792620 | Grupo de Estudos Multicentricos em Onco-Hematologia |
Multiple Myeloma Stage I
|
November 20, 2018 | Phase 3 |
| NCT04895917 | IRCCS Policlinico S. Matteo |
AL Amyloidosis
|
June 23, 2021 | Phase 2 |
| NCT00574288 | Janssen Research & Development, LLC |
Multiple Myeloma
|
March 26, 2008 | Phase 2 |
| NCT05218603 | PETHEMA Foundation|Janssen, LP|Adknoma Health Research |
Multiple Myeloma|Non-eligible for Autologous Stem Cell Transplantation (ASCT)
|
November 30, 2021 | |
| NCT03606577 | Nantes University Hospital |
Multiple Myeloma
|
July 30, 2019 | Phase 2 |
| NCT02343042 | Karyopharm Therapeutics Inc |
Multiple Myeloma
|
October 2015 | Phase 1|Phase 2 |
| NCT04304144 | Caelum Biosciences, Inc.|Alexion Pharmaceuticals |
AL Amyloidosis
|
March 18, 2020 | Phase 2 |
| NCT02431208 | Hoffmann-La Roche |
Multiple Myeloma
|
July 22, 2015 | Phase 1 |
| NCT05137054 | Regeneron Pharmaceuticals |
Multiple Myeloma
|
August 17, 2022 | Phase 1 |
| NCT03896737 | European Myeloma Network|EMN Research Italy |
Multiple Myeloma
|
April 16, 2019 | Phase 2 |
| NCT02918331 | Janssen Pharmaceutical K.K. |
Multiple Myeloma
|
September 2016 | Phase 1 |
| NCT04288765 | Grupo Cooperativo de Hemopatías Malignas |
Multiple Myeloma
|
March 1, 2020 | Phase 3 |
| NCT04166565 | European Myeloma Network|Janssen, LP |
Multiple Myeloma|Extramedullary Plasmacytoma
|
October 31, 2019 | Phase 2 |
| NCT05004259 | Dartmouth-Hitchcock Medical Center |
Hemolytic Anemia
|
March 21, 2022 | Phase 1 |
| NCT03188172 | University of Leeds|Myeloma UK|Celgene|Janssen, LP |
Multiple Myeloma
|
September 28, 2017 | Phase 2 |
| NCT03290950 | Memorial Sloan Kettering Cancer Center|Janssen Pharmaceuticals |
Multiple Myeloma
|
September 25, 2017 | Phase 2 |
| NCT02316106 | Janssen Research & Development, LLC |
Multiple Myeloma
|
May 20, 2015 | Phase 2 |
| NCT04052880 | Ajai Chari|Janssen, LP|Icahn School of Medicine at Mount Sinai |
Newly Diagnosed Multiple Myeloma
|
October 24, 2019 | Phase 2 |
| NCT04925193 | University of Colorado, Denver|Karyopharm Therapeutics Inc|National Cancer Institute (NCI) |
Multiple Myeloma in Relapse
|
November 18, 2021 | Phase 2 |
| NCT03993912 | University Hospital, Lille |
Multiple Myeloma
|
October 17, 2019 | Phase 3 |
| NCT05205252 | Epizyme, Inc. |
Relapsed+Refractory
|
December 22, 2021 | Phase 1|Phase 2 |
| NCT04703621 | Ostfold Hospital Trust|Haukeland University Hospital|Oslo University Hospital|University Hospital, Akershus|Henri Mondor University Hospital|Odense University Hospital |
ITP
|
January 21, 2021 | Phase 2 |
| NCT03004287 | University of Arkansas|Janssen, LP |
Multiple Myeloma
|
July 1, 2017 | Phase 2 |
| NCT03035357 | M.D. Anderson Cancer Center|Janssen-Cilag div. of Johnson&Johnson SE |
Malignant Neoplasms of Male Genital Organs|Prostate Cancer
|
March 1, 2017 | Phase 2 |
| NCT03067571 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
High Risk Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia
|
October 27, 2017 | Phase 2 |
| NCT03742297 | PETHEMA Foundation |
Newly Diagnosed Multiple Myeloma
|
October 22, 2018 | Phase 3 |
| NCT03221634 | Merck Sharp & Dohme LLC |
Multiple Myeloma
|
August 1, 2017 | Phase 2 |
| NCT04566328 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Plasma Cell Myeloma|RISS Stage I Plasma Cell Myeloma|RISS Stage II Plasma Cell Myeloma
|
October 27, 2020 | Phase 3 |
| NCT05561049 | The First Affiliated Hospital of Soochow University |
Newly Diagnosed Multiple Myeloma
|
October 1, 2022 | |
| NCT03095118 | Fernando Fervenza|Mayo Clinic |
Membranoproliferative Glomerulonephritis
|
September 7, 2017 | Phase 2 |
| NCT03158688 | Amgen |
Relapsed Multiple Myeloma|Refractory Multiple Myeloma
|
June 13, 2017 | Phase 3 |
| NCT03490344 | Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC |
Multiple Myeloma
|
May 3, 2018 | Phase 2 |
| NCT03481556 | Oncopeptides AB |
Multiple Myeloma
|
April 16, 2018 | Phase 1|Phase 2 |
| NCT03556332 | Memorial Sloan Kettering Cancer Center|Janssen Pharmaceuticals |
Multiple Myeloma
|
July 2, 2018 | Phase 2 |
| NCT03432741 | Mayo Clinic|National Cancer Institute (NCI) |
Breast Adenocarcinoma|Metastatic Breast Carcinoma|Recurrent Breast Carcinoma|Recurrent Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Breast Carcinoma|Refractory Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Nodal Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Breast Cancer AJCC v6 and v7
|
March 27, 2018 | Phase 1 |
| NCT03500445 | University of Chicago|Janssen Scientific Affairs, LLC|Amgen |
Myeloma|Multiple Myeloma
|
February 13, 2019 | Phase 2 |
| NCT04065789 | Tel-Aviv Sourasky Medical Center |
Myeloma Multiple|Myeloma, Plasma-Cell|Myeloma-Multiple|Plasma Cell Myeloma
|
May 2, 2018 | Phase 2 |
| NCT03439293 | Takeda |
Multiple Myeloma
|
March 13, 2018 | Phase 2 |
| NCT04933539 | National Cancer Institute (NCI)|Janssen Scientific Affairs, LLC|National Institutes of Health Clinical Center (CC) |
Multiple Myeloma
|
October 31, 2022 | Phase 2 |
| NCT04972942 | New York Medical College |
T-cell Acute Lymphoblastic Leukemia|T-Cell Acute Lymphoblastic Lymphoma
|
September 2021 | Phase 2 |
| NCT02807558 | Syros Pharmaceuticals |
Acute Myeloid Leukemia|Myelodysplastic Syndrome
|
August 2016 | Phase 2 |
| NCT03679624 | Weill Medical College of Cornell University|Janssen Scientific Affairs, LLC|Mayo Clinic |
Waldenstrom Macroglobulinemia|Waldenstrom´s Disease|Waldenström; Hypergammaglobulinemia|Waldenstrom´s Macroglobulinemia Recurrent|Waldenstrom´s Macroglobulinemia of Lymph Nodes|Waldenstrom´s Macroglobulinaemia, Without Mention of Remission|Waldenstrom´s Macroglobulinemia Refractory
|
July 30, 2020 | Phase 2 |
| NCT02116569 | Janssen Pharmaceutical K.K. |
Multiple Myeloma
|
April 2014 | Phase 1 |
| NCT04667663 | Cancer Trials Ireland|Janssen Pharmaceuticals|Celgene |
Multiple Myeloma
|
November 2021 | Phase 1 |
| NCT02944565 | Ohio State University Comprehensive Cancer Center |
Plasma Cell Myeloma
|
February 22, 2017 | Phase 2 |
| NCT04176718 | Andrew Yee, MD|Amgen|Janssen Research & Development, LLC|Massachusetts General Hospital |
Multiple Myeloma|Refractory Multiple Myeloma|Multiple Myeloma in Relapse|Relapse
|
May 18, 2020 | Phase 2 |
| NCT01998971 | Janssen Research & Development, LLC |
Multiple Myeloma
|
February 18, 2014 | Phase 1 |
| NCT05623020 | Pfizer |
Multiple Myeloma
|
November 15, 2022 | Phase 3 |
| NCT04223661 | Tyler Davis, MD, FACP|Janssen Scientific Affairs, LLC|Indiana Institute for Medical Research|Indiana University |
Multiple Myeloma
|
December 6, 2021 | Phase 2 |
| NCT02773030 | Celgene |
Multiple Myeloma
|
October 14, 2016 | Phase 1|Phase 2 |
| NCT05243342 | Genentech, Inc. |
Multiple Myeloma
|
April 28, 2022 | Phase 1 |
| NCT04131309 | European Myeloma Network|Janssen Pharmaceutica |
Light Chain (AL) Amyloidosis, Stage 3B
|
September 23, 2019 | Phase 2 |
| NCT04782687 | US Oncology Research|Karyopharm Therapeutics Inc |
Multiple Myeloma|Myeloma Multiple|Kahler Disease|Myeloma, Plasma Cell|Myeloma-Multiple|Myelomatosis|Plasma Cell Myeloma
|
September 10, 2021 | Phase 2 |
| NCT04810754 | Charite University, Berlin, Germany|Janssen-Cilag G.m.b.H|Labor Berlin-Charité Vivantes G.m.b.H|Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)|Charité Clinical Trial Office (CTO) |
Systemic Lupus Erythematosus
|
June 30, 2021 | Phase 2 |
| NCT05250973 | Janssen Research & Development, LLC |
Amyloidosis
|
March 1, 2022 | Phase 2 |
| NCT04251065 | Fondazione Italiana Linfomi ONLUS |
Refractory T-Cell Lymphoma|Relapsed T-Cell Lymphoma
|
September 3, 2020 | Phase 2 |
| NCT03180736 | European Myeloma Network|Janssen Research & Development, LLC |
Multiple Myeloma
|
June 12, 2017 | Phase 3 |
| NCT03068351 | Hoffmann-La Roche |
Multiple Myeloma
|
June 26, 2017 | Phase 1 |
| NCT04302324 | Weill Medical College of Cornell University|Janssen Scientific Affairs, LLC |
Multiple Myeloma|Refractory Multiple Myeloma|Relapse Multiple Myeloma
|
October 28, 2021 | Phase 2 |
| NCT01415882 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
January 31, 2012 | Phase 2 |
| NCT02488759 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
Various Advanced Cancer
|
October 13, 2015 | Phase 1|Phase 2 |
| NCT03734198 | French Innovative Leukemia Organisation|Janssen, LP |
Relapsed or Refractory Chronic Lymphocytic Leukemia
|
December 19, 2018 | Phase 2 |
| NCT02807454 | Celgene |
Multiple Myeloma
|
July 7, 2016 | Phase 2 |
| NCT04133636 | Janssen Research & Development, LLC |
Multiple Myeloma
|
November 7, 2019 | Phase 2 |
| NCT03757221 | University Hospital, Caen |
Multiple Myeloma
|
February 7, 2019 | Phase 2 |
| NCT05020236 | Pfizer |
Multiple Myeloma
|
October 4, 2021 | Phase 3 |
| NCT03236428 | Dana-Farber Cancer Institute|Janssen Pharmaceuticals|Multiple Myeloma Research Consortium|Blood Cancer Research Partnership|The Leukemia and Lymphoma Society |
Monoclonal Gammopathy|Smoldering Multiple Myeloma
|
November 24, 2017 | Phase 2 |
| NCT04088903 | Ronald Witteles|Stanford University |
Allosensitization|Heart Transplant Failure and Rejection
|
April 1, 2021 | Phase 1 |
| NCT02252172 | Janssen Research & Development, LLC |
Multiple Myeloma
|
February 16, 2015 | Phase 3 |
| NCT04892264 | Mayo Clinic|National Cancer Institute (NCI) |
Plasma Cell Myeloma|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
June 4, 2021 | Phase 1|Phase 2 |
| NCT04661137 | Hackensack Meridian Health|Karyopharm Therapeutics Inc |
Multiple Myeloma
|
March 16, 2021 | Phase 2 |
| NCT04139304 | AIDS Malignancy Consortium|National Cancer Institute (NCI)|Janssen Scientific Affairs, LLC|Montefiore Medical Center|Memorial Sloan Kettering Cancer Center|AIDS and Cancer Specimen Resource|The Emmes Company, LLC |
Plasmablastic Lymphoma|Ann Arbor Stage I Diffuse Large B-Cell Lymphoma|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
|
May 24, 2021 | Early Phase 1 |
| NCT02497378 | Janssen Pharmaceutical K.K. |
Multiple Myeloma
|
July 10, 2015 | Phase 1 |
| NCT05556616 | Takeda |
Multiple Myeloma
|
October 27, 2022 | Phase 1 |
| NCT04915248 | Fondazione Italiana Linfomi ONLUS|Janssen-Cilag S.p.A. |
Plasmablastic Lymphoma
|
July 11, 2022 | Phase 2 |
| NCT04181827 | Janssen Research & Development, LLC |
Multiple Myeloma
|
June 12, 2020 | Phase 3 |
| NCT04230031 | Wake Forest University Health Sciences|Janssen Research & Development, LLC |
Multiple Myeloma
|
July 2, 2021 | Phase 2 |
| NCT04280328 | Corvus Pharmaceuticals, Inc. |
Multiple Myeloma
|
February 20, 2020 | Phase 1 |
| NCT01985126 | Janssen Research & Development, LLC |
Multiple Myeloma
|
September 27, 2013 | Phase 2 |
| NCT04396496 | University of Arkansas|Janssen Scientific Affairs, LLC |
POEMS Syndrome
|
September 22, 2020 | Phase 2 |
| NCT05392946 | Mayo Clinic|National Cancer Institute (NCI) |
Plasma Cell Myeloma
|
August 11, 2022 | Phase 1|Phase 2 |
| NCT04140162 | University of Michigan Rogel Cancer Center|Janssen Scientific Affairs, LLC |
Multiple Myeloma
|
October 5, 2020 | Phase 2 |
| NCT02927925 | Janssen Research & Development, LLC |
Lymphoma
|
February 14, 2017 | Phase 2 |
| NCT04649060 | Oncopeptides AB |
Relapse Multiple Myeloma|Multiple Myeloma
|
December 7, 2020 | Phase 3 |
| NCT03942224 | Emory University|Takeda|Janssen, LP |
Plasma Cell Myeloma
|
July 3, 2019 | Phase 2 |
| NCT04151667 | H. Lee Moffitt Cancer Center and Research Institute|Janssen Scientific Affairs, LLC |
Multiple Myeloma
|
November 22, 2019 | Phase 2 |
| NCT05300451 | Barry A. Boilson|Janssen Biotech, Inc.|Mayo Clinic |
Antibody-mediated Rejection|Cardiac Transplant
|
March 31, 2022 | Phase 2 |
| NCT02951819 | Janssen Scientific Affairs, LLC |
Multiple Myeloma
|
November 9, 2016 | Phase 2 |
| NCT03450057 | Hellenic Society of Hematology|Janssen Pharmaceuticals |
Multiple Myeloma
|
February 15, 2018 | Phase 2 |
| NCT03000452 | Celgene |
Multiple Myeloma
|
March 14, 2017 | Phase 2 |
| NCT04246047 | GlaxoSmithKline |
Multiple Myeloma
|
May 7, 2020 | Phase 3 |
| NCT04922723 | West Virginia University |
Glioblastoma
|
October 2022 | Phase 1|Phase 2 |
| NCT04352205 | Emory University|Janssen Scientific Affairs, LLC|National Cancer Institute (NCI) |
Plasma Cell Myeloma|Renal Failure
|
May 7, 2020 | Phase 2 |
| NCT04230304 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia+Small Lymphocytic Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma
|
September 16, 2020 | Phase 2 |
| NCT04136756 | Nektar Therapeutics |
Multiple Myeloma|Non-Hodgkin Lymphoma|Indolent Non-Hodgkin Lymphoma
|
October 7, 2019 | Phase 1 |
| NCT03841565 | Academic and Community Cancer Research United|Janssen Scientific Affairs, LLC|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma
|
August 7, 2020 | Phase 2 |
| NCT04474938 | Peking Union Medical College Hospital|Xian-Janssen Pharmaceutical Ltd. |
Amyloidosis; Systemic
|
May 24, 2021 | Phase 2 |
| NCT02195479 | Janssen Research & Development, LLC |
Multiple Myeloma
|
December 9, 2014 | Phase 3 |
| NCT03937635 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Smoldering Plasma Cell Myeloma
|
April 30, 2019 | Phase 3 |
| NCT04407442 | University of California, San Francisco|Janssen Pharmaceuticals|Multiple Myeloma Research Foundation |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
November 30, 2020 | Phase 2 |
| NCT05552222 | Janssen Research & Development, LLC |
Multiple Myeloma
|
October 25, 2022 | Phase 3 |
| NCT04614636 | Fate Therapeutics |
Acute Myeloid Leukemia|AML, Adult|Multiple Myeloma|Myeloma
|
October 17, 2020 | Phase 1 |
| NCT05486481 | Sandy Wong, MD|Janssen Pharmaceuticals|AbbVie|University of California, San Francisco |
AL Amyloidosis|Light Chain (AL) Amyloidosis|Systemic Light Chain Disease
|
January 15, 2023 | Phase 1|Phase 2 |
| NCT04656951 | University of Cologne|Janssen-Cilag G.m.b.H |
Multiple Myeloma
|
June 1, 2021 | Phase 2 |
| NCT02519452 | Janssen Research & Development, LLC |
Multiple Myeloma
|
October 22, 2015 | Phase 1 |
| NCT04868838 | Mayo Clinic |
Lupus Nephritis
|
April 20, 2021 | Phase 2 |
| NCT05083169 | Janssen Research & Development, LLC |
Multiple Myeloma
|
October 14, 2021 | Phase 3 |
| NCT02874742 | Janssen Research & Development, LLC |
Multiple Myeloma
|
August 29, 2016 | Phase 2 |
| NCT03384654 | Janssen Research & Development, LLC |
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
May 14, 2018 | Phase 2 |
| NCT03695744 | Singapore General Hospital|International Myeloma Foundation|Janssen, LP |
Multiple Myeloma|Myeloma
|
October 2, 2019 | Phase 2 |
| NCT03992170 | Azienda Ospedaliera Universitaria Senese|Janssen-Cilag S.p.A. |
Myeloma Multiple
|
December 31, 2018 | Phase 2 |
| NCT05561387 | Southwest Oncology Group|National Cancer Institute (NCI) |
Plasma Cell Myeloma
|
December 1, 2022 | Phase 3 |
| NCT01592370 | Bristol-Myers Squibb|Janssen, LP |
Non-Hodgkin´s Lymphoma|Hodgkin Lymphoma|Multiple Myeloma
|
August 2, 2012 | Phase 1|Phase 2 |
| NCT04513639 | Oslo University Hospital|St. Olavs Hospital|Haukeland University Hospital|University Hospital of North Norway|University Hospital, Akershus|Helse Stavanger HF|Førde Central Hospital|Sorlandet Hospital HF|Nordlandssykehuset HF|The Hospital of Vestfold|Helse Nord-Trøndelag HF|Alesund Hospital|Sykehuset Ostfold |
Multiple Myeloma
|
August 27, 2020 | Phase 2|Phase 3 |
| NCT04910568 | Genentech, Inc.|Hoffmann-La Roche |
Multiple Myeloma
|
July 26, 2021 | Phase 1 |
| NCT05145296 | University Hospital, Grenoble|Bristol-Myers Squibb |
Sensitisation|Highly Sensitised Dialysis Patients
|
January 19, 2022 | Not Applicable |
| NCT05139225 | Memorial Sloan Kettering Cancer Center|Trillium Therapeutics Inc. |
Multiple Myeloma
|
October 28, 2021 | Phase 1 |
| NCT05054478 | Assistance Publique - Hôpitaux de Paris |
Plasma Cell Leukemia
|
October 2021 | Phase 2 |
| NCT03477539 | Mayo Clinic|National Cancer Institute (NCI) |
Plasma Cell Myeloma
|
April 9, 2018 | Phase 2 |
| NCT03710603 | European Myeloma Network|Janssen Research & Development, LLC |
Multiple Myeloma
|
December 14, 2018 | Phase 3 |
| NCT03301220 | Janssen Research & Development, LLC |
Smoldering Multiple Myeloma
|
November 7, 2017 | Phase 3 |
| NCT05562882 | Institute of Hematology & Blood Diseases Hospital |
Immune Thrombocytopenia
|
October 15, 2022 | Early Phase 1 |
| NCT02852837 | Janssen Research & Development, LLC |
Multiple Myeloma
|
September 26, 2016 | Phase 1 |
| NCT05572229 | University Hospital, Lille |
Multiple Myeloma
|
February 2023 | Phase 2 |
| NCT03697629 | Canadian Myeloma Research Group |
Multiple Myeloma in Relapse
|
December 3, 2018 | Phase 2 |
| NCT04956302 | Abdullah Khan|Ohio State University Comprehensive Cancer Center |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
September 27, 2021 | Phase 1 |
| NCT03311828 | City of Hope Medical Center |
Recurrent Plasma Cell Myeloma|Plasma Cell Myeloma|Secondary Amyloidosis
|
February 21, 2018 | Phase 1 |
| NCT04204980 | Assistance Publique - Hôpitaux de Paris|Janssen, LP |
Allosensitization|Kidney Transplant Rejection|Antibody-mediated Rejection
|
February 18, 2020 | Phase 1|Phase 2 |
| NCT05182073 | Fate Therapeutics |
Multiple Myeloma|Myeloma
|
November 24, 2021 | Phase 1 |
| NCT02841033 | Boston Medical Center|Janssen Pharmaceuticals |
AL Amyloidosis
|
March 20, 2017 | Phase 1|Phase 2 |
| NCT03768960 | Johnson & Johnson Private Limited |
Multiple Myeloma
|
June 10, 2019 | Phase 4 |
| NCT03012880 | Mayo Clinic|National Cancer Institute (NCI) |
Plasma Cell Myeloma
|
April 12, 2017 | Phase 2 |
| NCT04895410 | AbbVie |
Multiple Myeloma
|
January 17, 2022 | Phase 1 |
| NCT05050097 | Janssen Research & Development, LLC |
Multiple Myeloma
|
September 22, 2021 | Phase 1 |
| NCT03652064 | Janssen Research & Development, LLC |
Multiple Myeloma
|
November 6, 2018 | Phase 3 |
| NCT03098550 | Bristol-Myers Squibb|Janssen Biotech, Inc. |
Advanced Cancer
|
June 15, 2017 | Phase 1|Phase 2 |
| NCT01615029 | Janssen Research & Development, LLC |
Multiple Myeloma
|
June 26, 2012 | Phase 1|Phase 2 |
| NCT03234972 | Janssen Research & Development, LLC |
Multiple Myeloma
|
November 30, 2017 | Phase 3 |
| NCT04775550 | Omar Nadeem|Janssen, LP|Dana-Farber Cancer Institute |
High-risk Smoldering Multiple Myeloma|Multiple Myeloma
|
April 9, 2021 | Phase 2 |
| NCT04070378 | Marc L Gordon, MD|Janssen Scientific Affairs, LLC|Northwell Health |
Alzheimer Disease
|
November 6, 2019 | Phase 2 |
| NCT02136134 | Janssen Research & Development, LLC |
Multiple Myeloma
|
August 15, 2014 | Phase 3 |
| NCT05590377 | Takeda |
Multiple Myeloma
|
December 15, 2022 | Phase 1|Phase 2 |
| NCT04108195 | Janssen Research & Development, LLC |
Multiple Myeloma
|
February 21, 2020 | Phase 1 |
| NCT05527340 | PETHEMA Foundation|Celgene-BMS|Janssen-Cilag, S.A.|LIDESEC |
Multiple Myeloma
|
September 2022 | Phase 2 |
| NCT03011034 | Janssen Research & Development, LLC |
Myelodysplastic Syndromes
|
February 14, 2017 | Phase 2 |
| NCT03651128 | Celgene |
Multiple Myeloma
|
April 16, 2019 | Phase 3 |
| NCT02816476 | University Hospital, Limoges |
Amyloidosis
|
September 2016 | Phase 2 |
| NCT03763162 | M.D. Anderson Cancer Center|Takeda |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
January 17, 2019 | Phase 2 |
| NCT03591744 | City of Hope Medical Center|National Cancer Institute (NCI) |
Plasma Cell Leukemia
|
October 25, 2018 | Phase 1 |
| NCT05257083 | European Myeloma Network|Janssen Research & Development, LLC |
Multiple Myeloma
|
December 2022 | Phase 3 |
| NCT01946477 | Celgene |
Multiple Myeloma
|
May 29, 2014 | Phase 2 |
| NCT04268498 | University of Miami|Amgen|Janssen Pharmaceuticals |
Multiple Myeloma
|
February 11, 2020 | Phase 2 |
| NCT03023423 | Janssen Research & Development, LLC|Genentech, Inc. |
Carcinoma, Non-Small-Cell Lung
|
December 23, 2016 | Phase 1|Phase 2 |
| NCT03346135 | City of Hope Medical Center|National Cancer Institute (NCI) |
Plasma Cell Myeloma|Secondary Amyloidosis
|
July 17, 2019 | Phase 2 |
| NCT05511428 | Thomas Jefferson University|Janssen Scientific Affairs, LLC |
Plasma Cell Myeloma
|
December 2022 | Not Applicable |
| NCT03473730 | M.D. Anderson Cancer Center|Janssen Research & Development, LLC|National Cancer Institute (NCI) |
Bladder Urothelial Carcinoma|Clear Cell Renal Cell Carcinoma|Malignant Urinary System Neoplasm|Metastatic Kidney Carcinoma|Stage IV Renal Cell Cancer AJCC v8
|
May 29, 2018 | Early Phase 1 |
| NCT05438043 | Janssen Research & Development, LLC |
Multiple Myeloma
|
December 23, 2022 | Phase 3 |
| NCT03447808 | Jennifer Woyach|Ohio State University Comprehensive Cancer Center |
Chronic Lymphocytic Leukemia
|
August 16, 2018 | Phase 1 |
| NCT03177460 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Prostate Adenocarcinoma|Stage III Prostate Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8|Testosterone Greater Than 150 ng+dL
|
June 7, 2017 | Phase 1 |
| NCT04497961 | Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs, LLC |
Multiple Myeloma
|
August 28, 2020 | Phase 2 |
| NCT02076009 | Janssen Research & Development, LLC |
Multiple Myeloma
|
May 23, 2014 | Phase 3 |
| NCT02955810 | National University of Ireland, Galway, Ireland|Janssen Pharmaceuticals|Cancer Trials Ireland |
Multiple Myeloma
|
November 2016 | Phase 1 |
| NCT04586426 | Janssen Research & Development, LLC |
Multiple Myeloma
|
December 15, 2020 | Phase 1 |
| NCT04024384 | Assistance Publique - Hôpitaux de Paris |
Multiple Myeloma
|
July 2019 | Phase 2 |
| NCT04700176 | Hackensack Meridian Health|Janssen, LP |
Multiple Myeloma
|
May 2, 2022 | Phase 2 |
Appearance
Liquid
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Ghose J, Viola D, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018;7(10):e1486948. Published 2018 Jul 23.
- [2] de Weers M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848.
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.